Functional microbiome analysis
Determine microbiota composition in human subjects, and allow for accurate measurement and monitoring of microbiomes in various stages of scientific research to accelerate advancement and discovery. TNO has a wide range of available tools to increase understanding of the impact and interaction of the microbiome on human health. This is key to determining how various diseases change the body, and how various drugs can impact that change.
Learn more about microbiome for health
Download the presentation
TNO allows the analysis of microbiota compositions on samples from a broad range of origins and matrices. We use techniques such as amplicon sequencing, whole genome sequencing (WGS), metagenomics, RNAseq and qPCR.
TNO can also support every aspect of management of these large data sets. From data handling and storage, statistical and biological analysis and interpretation to advanced machine-learning tools to identify patterns in the complex data. Furthermore, our platforms allow for high-throughput ex-vivo analysis of shifts in microbiota upon exposure to compounds, ingredients or other changes. This can accelerate understanding of drug interactions and metabolism, and the relation between microbiome and diseases such as IBD and colon cancer, which will lead to further understanding of how shifts in the microbiome impact health.
Through TNO’s intestinal screening model (i-screen), biotech companies can measure and track the effects of compounds metabolised by human intestinal microbiota. The i-screen platform allows safe and accurate in vitro testing of the microbiota’s potential to metabolise various drug candidates. Testing can be conducted at the earliest stages of drug development, so adverse effects or metabolites can be identified in pre-clinical stages, thereby saving time, effort and costs.
Each i-screen can simultaneously be exposed to a variety of different conditions, thereby allowing multiple compounds or concentrations to be tested at once. In all cases, potential metabolites can be identified in the earliest stages of development, with human accuracy, without the need for regulatory processing.
TNO assists in the better understanding of host microbe interactions and offers host platforms to analyse interactions with the intestinal epithelium. This includes the use of intestinal organoids: stem-cell-based structures that contain all cell types in an in vitro system, just as they appear in vivo. In addition, InTESTine, a new in vitro intestinal model using ex vivo intestinal epithelium, uses healthy porcine or human tissue to model and predict drug absorption in human subjects. InTESTine allows the simultaneous study of multiple intestinal segments (duodenum, jejunum, ileum & colon) to determine regional differences in absorption under controlled conditions. This enables screening for toxicity (safety), early immune responses, and/or endocrine responses to potential drug therapies at the pre-clinical stage.
TNO can also put its microbiome expertise to work to conduct extensive toxicology testing and analysis. Using a variety of techniques and platforms, we can help investigate the interplay between microbiota and host, and the extent to which certain microbiota have a toxic effect on the human body.
Webinar 'What's new in in vitro microbiome and ex vivo intestinal models for gut health'
On November 9th 2021 the webinar 'What's new in in vitro microbiome and ex vivo intestinal models for gut health' took place. You are able to register and review the webinar via the video below. The webinar takes 50 minutes.
Looking for another expert?View all experts
PK Studies AMS
With TNO’s microtracer expertise, drug development becomes a streamlined and targeted process.
Target safety assessment
Our unique set of assessments and web-based target triaging platform TargetTri, can help to make informed decision making easy with transparent, knowledge-driven expert views on target efficacy, safety liabilities, and risk mitigation.
Advanced microtracer studies
A drug’s ADME and ADR's are often difficult to predict. At TNO we have developed in vitro and ex vivo platforms that can help to make this easier.
To better estimate the efficacy of drug candidates, TNO is developing various translational models that help to accurately predict events in the human body.